Cure My Disease

Don't miss your cure!

 Log in / Sign up

Fat mapping MRI could spot breast cancer years earlier

NCT ID NCT05268913

Diagnosis Sponsor: University of Aberdeen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 31, 2026 · Last updated Sep 01, 2026 · Updated 1 time

Summary

Researchers are testing whether a standard MRI scanner can be used to create detailed 3D maps of fat molecules in the breast. The idea is that changes in fat composition may appear before cancer develops, so this could help detect very early breast cancers. The study will compare breast fat patterns in premenopausal women with high genetic risk, women with breast cancer, and women with obesity. Participants will have an MRI scan and a fasting blood test.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
MRI scan and blood test
What this could lead to
If this works, it could lead to a more accurate, non-invasive screening method for early breast cancer, especially in high-risk premenopausal women.
What could go wrong
This is a small, early-stage study with 30 participants. The MRI technique may not reliably distinguish early cancers from normal tissue, and results may not apply to broader populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

30 people

The number who actually took part.

Started

Nov 2022

Finished

May 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Women with BRCA1/2 genes will be identified and approached by the geneticist and research nurse at the family high risk clinic. Patients will be identified and approached by the breast surgeon and breast care nurse at the results clinic. Women with obesity will be identified through organisation emails, word of month and leaflets in the community health clinic for residents of Aberdeenshire.

Ages

18 to 55 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: \- Women with BRCA1/2 genes: * female 18-55 years old, premenopausal * BRCA 1/2 gene carriers * not having any metabolic disorders (e.g., diabetes) * not on any long term medications that may affect lipid metabolism (e.g., statins) * BMI \< 30 Women with breast cancer (no obesity): * females 18-55 years old, premenopausal * confirmed diagnosis of invasive ductal carcinoma of the breast * not having any metabolic disorders (e.g., diabetes) * not on any long term medications that may affect lipid metabolism (e.g., statins) * BMI \< 30 Women with breast cancer (obesity): * BMI \> 30 * otherwise as women with breast cancer Women with obesity: * females 18-55 years old, premenopausal * not having any metabolic disorders (e.g., diabetes) * not on any long term medications that may affect lipid metabolism (e.g., statins) * BMI \> 30 Exclusion Criteria: * females under 18 or over 55 years old, postmenopausal * males * have metabolic disorders (e.g., diabetes) * on long term medications that may affect lipid metabolism (e.g., statins) * contraindicated for MR investigation (poor renal function and metal implants) * (for patients) concurrent cancer in other sites * (for patients) started hormone treatment, chemotherapy or breast surgery * non-English speakers

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm invasive ductal breast carcinoma obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer

Contacts and locations

Locations

  • Aberdeen Biomedical Imaging Centre

    Aberdeen, Aberdeenshire, AB25 2ZD, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.